The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

Monica Bellei, Francine M Foss, Andrei R Shustov, Steven M Horwitz, Luigi Marcheselli, Won Seog Kim, Maria E Cabrera, Ivan Dlouhy, Arnon Nagler, Ranjana H Advani, Emanuela A Pesce, Young-Hyeh Ko, Virginia Martinez, Silvia Montoto, Carlos Chiattone, Alison Moskowitz, Michele Spina, Irene Biasoli, Martina Manni, Massimo Federico, International T-cell Project Network, Monica Bellei, Francine M Foss, Andrei R Shustov, Steven M Horwitz, Luigi Marcheselli, Won Seog Kim, Maria E Cabrera, Ivan Dlouhy, Arnon Nagler, Ranjana H Advani, Emanuela A Pesce, Young-Hyeh Ko, Virginia Martinez, Silvia Montoto, Carlos Chiattone, Alison Moskowitz, Michele Spina, Irene Biasoli, Martina Manni, Massimo Federico, International T-cell Project Network

Abstract

This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 patients who received first-line treatment, 436 (47%) were identified as refractory and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months (range 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, including 12 refractory and 22 relapsed patients. After a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively (P<0.001). Patients receiving or not salvage bone marrow transplantation had a 3-year survival of 48% and 18%, respectively (P<0.001). In a univariate Cox regression analysis, refractory disease was associated with a higher risk of death (HR=1.43, P=0.001), whereas late relapse (>12 months, HR 0.57, P=0.001) and salvage therapy with transplantation (HR=0.36, P<0.001) were associated with a better OS. No difference was found in OS with respect to histology. This study accurately reflects outcomes for patients treated according to standards of care worldwide. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after relapse or progression. Patients with chemotherapy sensitive disease who relapsed after more than 12 months might benefit from consolidation bone marrow transplantation.

Trial registration: ClinicalTrials.gov NCT01142674.

Copyright© 2018 Ferrata Storti Foundation.

Figures

Figure 1.
Figure 1.
Flow chart of patients included in the analysis. CR: complete remission.
Figure 2.
Figure 2.
Survival after relapse (SAR). (A) SAR curve of 633 refractory/relapsed patients. (B) SAR by status: refractory versus relapse. Refractory patients are those with primary refractoriness.
Figure 3.
Figure 3.
Outcomes for refractory/relapsed patients depending on histological subtypes. PTCL-NOS: peripheral T-cell lymphoma not otherwise specified; AITL: angioimmunoblastic T-cell lymphoma; ALCL (−): anaplastic large cell lymphoma, anaplastic lymphoma kinase negative; ALCL (+): anaplastic large cell lymphoma, anaplastic lymphoma kinase positive; NKTCL: extranodal NK/T-cell lymphoma.
Figure 4.
Figure 4.
Survival after relapse (SAR) by salvage therapy including or not hematopoietic cell transplantation (HCT). Elig: eligible; Not elig: not eligible; CR: complete remission; PR: partial remission.

References

    1. Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
    1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
    1. Adams SV, Newcomb PA, Shustov AR. Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States. J Clin Oncol. 2016;34(9):963–971.
    1. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood. 1997;89(12):4514–4520.
    1. Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol. 1998;9(8):849–855.
    1. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood. 1998;92(1):76–82.
    1. Mak V, Hamm J, Chhanabhai M, et al. Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. J Clin Oncol. 2013;31(16):1970–1976.
    1. Biasoli I, Cesaretti M, Bellei M, et al. Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry. Hematol Oncol. 2015;33(3):147–151.
    1. Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99214–227.
    1. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues: Pathology and Genetics. Lyon, France: IARC Press; 2001.
    1. Federico M, Bellei M, Pesce E, et al. T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma. Rev Bras Hematol Hemoter. 2009;31(2):21–25.
    1. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
    1. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
    1. Piccaluga PP, Fuligni F, De Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol. 2013;31(24):3019–3025.
    1. Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–2923.
    1. O’Connor OA, Bhagat G, Ganapathi K, et al. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice. Clin Cancer Res. 2014;20(20):5240–5254.
    1. Inghirami G, Chan WC, Pileri S. Peripheral T-cell and NK cell lymphoproliferative disorders: Cell of origin, clinical and pathological implications. Immunol Rev 2015;263(1):124–159.
    1. Coiffier B, Federico M, Caballero D, et al. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat Rev. 2014;40(9):1080–1088.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir